Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5 alpha)-, phosphate (1:1) | 14982-61-7

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5 alpha)-, phosphate (1:1)
• 英文别名: (4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;phosphoric acid
• CAS: 14982-61-7
• 化学式: C18H24NO7P
• 分子量: 397.4
• InChiKey: YWVTXAJDZQFZGH-RNWHKREASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.0
• 重原子数：
  27
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  117
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• Encased tamper resistant controlled release dosage forms
  申请人：Purdue Pharma L.P.

  公开号：EP2826467A1

  公开（公告）日：2015-01-21

  In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material comprising polyethylene oxide having an average molecular weight from about 300,000 to about 10,000,000; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material comprising polyethylene oxide having an average molecular weight from about 1,000,000 to about 10,000,000.

  在某些实施方案中，本发明涉及一种固体控释剂型，该剂型包括：内核，内核包括分散在第一种基质材料中的第一部分阿片类镇痛剂，第一种基质材料包括聚氧化乙烯，聚氧化乙烯的平均分子量约为 300,000 至 10,000,000 ；以及外壳，外壳包裹内核，外壳包括分散在第二种基质材料中的第二部分阿片类镇痛剂，第二种基质材料包括聚氧化乙烯，聚氧化乙烯的平均分子量约为 1,000,000 至 10,000,000 。
• Methods of manufacturing oral formulations
  申请人：PURDUE PHARMA L.P.

  公开号：US10022368B2

  公开（公告）日：2018-07-17

  A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.

  本发明公开了一种氢可酮口服固体控释剂型，该剂型包括镇痛有效量的氢可酮或其药学上可接受的盐以及控释材料。
• Methods of manufacturing oral dosage forms
  申请人：Purdue Pharma L.P.

  公开号：US10076516B2

  公开（公告）日：2018-09-18

  A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.

  本发明公开了一种氢可酮固体口服控释剂型。该剂型包含镇痛有效量的氢可酮或其药学上可接受的盐，以及足量的控释材料，使该剂型适合每天两次给人类患者服用，该剂型的C12/Cmax比值为0.55至0.85，所述剂型可提供至少约12小时的治疗效果。
• Hydrocodone therapy
  申请人：——

  公开号：US20030077320A1

  公开（公告）日：2003-04-24

  A hydrocodone composition, a hydrocodone dosage form, and a method of administering hydrocodone are disclosed and indicated for hydrocodone therapy.

  本研究公开了一种氢可酮组合物、氢可酮剂型和氢可酮给药方法，适用于氢可酮治疗。
• Stabilized hydrocodone pharmaceutical compositions with ethylenediaminetetraacetic acid
  申请人：Whitehead Keith

  公开号：US20060205752A1

  公开（公告）日：2006-09-14

  Hydrocodone pharmaceutical formulations are stabilized with a stabilizing effective amount of ethylenediaminetetraacetic compound.

  氢可酮药物制剂使用有效含量的乙二胺四乙酸稳定剂进行稳定。